Honeywell has once again bet on the Bayou City for business. Photo courtesy of Parkway

A nearly $10 billion division of Honeywell International that primarily caters to the oil and gas industry has moved its headquarters to Houston.

On August 11, Charlotte, North Carolina-based Honeywell announced its Performance Materials and Technologies (PMT) division had completed its relocation to the Westchase area's nearly 1.5 million-square-foot CityWestPlace office complex where the company already has operations.

PMT joins one its units, Honeywell's Process Solutions business, at CityWestPlace. The Process Solutions business and about 750 employees relocated there from 1250 Sam Houston Parkway South in 2019.

At CityWestPlace, PMT is adding a customer center where it can showcase automation products and services.

With the PMT relocation, Honeywell now employs more than 850 people in Houston. Representatives of Honeywell decline to say where PMT was previously based.

"Houston [is] a diverse and rapidly growing city, and locating our headquarters here will help us meet our long-term needs to recruit and retain premier talent in our industry. It will also allow us to build closer, more impactful relationships with our Texas-based customers," Vimal Kapur, the new president and CEO of PMT, says in a news release.

Before coming to Houston to take the reins of PMT, Kapur was president of CEO of Atlanta-based Honeywell Building Technologies. He has worked at Honeywell for more than three decades.

Houston Mayor Sylvester Turner says PMT's move to Houston offers another example of how the city is leading innovation in the global energy sector.

"As the energy capital of the world, Houston has the talent and expertise to amplify Honeywell's sustainability work. And with their focus on key components of the energy transition, including carbon capture, energy storage and hydrogen, Honeywell's PMT business unit will serve as a critical partner in Houston's effort to lead the energy transition," Turner says.

PMT provides performance chemicals and materials, process technology, and automation technology for an array of industries, including oil and gas. It posted net sales of $9.4 billion in 2020, down from $10.8 billion in 2019. Honeywell, a Fortune 100 conglomerate, reported net sales of $32.6 billion last year.

Competitors of PMT include ABB, BASF, Dupont, and Emerson Electric.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.